Genomic Structural Variation in Cancer Susceptibility
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00996710|
Recruitment Status : Enrolling by invitation
First Posted : October 16, 2009
Last Update Posted : January 10, 2020
This study will look for new types of gene changes that may be related to cancer in some patients. Some gene changes (mutations) are passed on from parents to offspring (child). Other gene changes are new and are seen for the first time in a child. They are not seen in the parent.
Some of these gene changes may cause cancers in the offspring. We will look for gene changes by studying patients with cancer their parents and family members without cancer. In this study, we will be able to find gene changes that occur in the cancer patient but not in the rest of the family. Knowing the role that new gene changes play in cancer risk may help us find people at a higher risk of getting cancer.
|Condition or disease|
|Breast Cancer Colon Cancer Germ Cell Cancer Neuroblastoma Rectal Cancer Sarcoma|
|Study Type :||Observational|
|Estimated Enrollment :||1850 participants|
|Official Title:||Genomic Structural Variation in Cancer Susceptibility|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||October 2020|
- To determine the frequency of de novo germline copy number variants (CNVs) in cancer affected probands using an ascertainment of "trios" consisting of cancer patients and their unaffected biologic parents [ Time Frame: 2 years ]
- To explore the role of germline homozygosity in cancer susceptibility by determining the frequency and length of autozygous regions in patients with cancer [ Time Frame: 2 years ]and mechanisms of Mendelian inheritance, such as autosomal recessive, autosomal dominant, and X-linked, which upon initial ascertainment may be difficult to decipher.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00996710
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Zsofia Stadler, MD||Memorial Sloan Kettering Cancer Center|